Literature DB >> 23957825

Living status in patients over 85 years of age after TUVRP.

A H Li1, Y Zhang, H H Lu, F Zhang, S K Liu, H Wang, B H Zhang.   

Abstract

INTRODUCTION: To evaluate surgical risk and post-operative quality of living status in patients over 85 years of age after transurethral vaporization resection of the prostate (TUVRP).
METHODS: Sixty patients over 85 years of age underwent TUVRP were compared with 228 patients less than the age of 80 years. Group A was 60 patients greater than 85 years of age, Group B was 137 patients from 71 to 79 years of age, and Group C was 91 patients from 60 to 70 years of age.
RESULTS: In Group A, pre-operative ASA grade was higher than the other two groups, compared with Group C, p < 0.01. Operating time was 40.03 ± 18.90 min, compared in the three groups, p > 0.05. Follow-up was obtained in 49 (81.67%) patients; of them 10 patients were deaths with a survival time of 22.90 ± 11.14 months. In the 39 survivors, post-operative IPSS score was 11.17 ± 6.9, compared with Group B, p > 0.05 and Group C, p < 0.01. Quality of Life (QOL) index was 1.11 ± 0.80, compared with Group B, p < 0.001 and Group C, p < 0.01. Barthel Index score in 16 patients was >60 and the score was 82.81 ± 8.56 pre-operatively. The patients with >60 were increased to 19 cases and the score was improved to 90.93 ± 7.58 (p < 0.001) in follow-up.
CONCLUSION: Surgical risk in patients over 85 years of age was higher than patients less than the age of 80 years. A safety TUVRP could improve their voiding function and activities of daily living.

Entities:  

Mesh:

Year:  2013        PMID: 23957825     DOI: 10.3109/13685538.2013.826186

Source DB:  PubMed          Journal:  Aging Male        ISSN: 1368-5538            Impact factor:   5.892


  1 in total

1.  Transurethral cystolitholapaxy with the AH-1 stone removal system for the treatment of bladder stones of variable size.

Authors:  Aihua Li; Chengdong Ji; Hui Wang; Genqiang Lang; Honghai Lu; Sikuan Liu; Weiwu Li; Binghui Zhang; Wei Fang
Journal:  BMC Urol       Date:  2015-02-21       Impact factor: 2.264

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.